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NEOPLASIA
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the
interaction of multiple myeloma cells and osteoclasts
Sonia Vallet,1,2 Noopur Raje,1,3 Kenji Ishitsuka,1 Teru Hideshima,1 Klaus Podar,1 Shweta Chhetri,1 Samantha Pozzi,1
Iris Breitkreutz,1 Tanyel Kiziltepe,1 Hiroshi Yasui,1 Enrique M. Ocio,1 Norihiko Shiraishi,1 Janice Jin,1 Yutaka Okawa,1
Hiroshi Ikeda,1 Siddhartha Mukherjee,3 Nileshwari Vaghela,1 Diana Cirstea,1 Marco Ladetto,2 Mario Boccadoro,2 and
Kenneth C. Anderson1
1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 2Division of Hematology, University of
Turin, Turin, Italy; and 3Division of Hematology and Oncology, Massachusetts General Hospital, Boston
The interaction between osteoclasts (OCs)
and multiple myeloma (MM) cells plays a
key role in the pathogenesis of MM-
related osteolytic bone disease (OBD).
MM cells promote OC formation and, in
turn, OCs enhance MM cell proliferation.
Chemokines are mediators of MM effects
on bone and vice versa; in particular,
CCL3 enhances OC formation and pro-
motes MM cell migration and survival.
Here, we characterize the effects of
MLN3897, a novel specific antagonist of
the chemokine receptor CCR1, on both
OC formation and OC-MM cell interac-
tions. MLN3897 demonstrates significant
impairment of OC formation (by 40%) and
function (by 70%), associated with de-
creased precursor cell multinucleation
and down-regulation of c-fos signaling.
OCs secrete high levels of CCL3, which
triggers MM cell migration; conversely,
MLN3897 abrogates its effects by inhibit-
ing Akt signaling. Moreover, MM cell-
to-OC adhesion was abrogated by
MLN3897, thereby inhibiting MM cell sur-
vival and proliferation. Our results there-
fore show novel biologic sequelae of
CCL3 and its inhibition in both osteoclas-
togenesis and MM cell growth, providing
the preclinical rationale for clinical trials
of MLN3897 to treat OBD in MM. (Blood.
2007;110:3744-3752)
© 2007 by The American Society of Hematology
Introduction
Osteolytic bone disease (OBD), characterized by bone pain,
increased risk of fracture, and tumor-induced hypercalcemia, is
a frequent complication of multiple myeloma (MM). The yearly
incidence of skeletal-related events in patients with MM is
approximately 40%; in particular, vertebral fractures account for
12% to 30%, with significant clinical and economic impact.1
OBD is due to an imbalance between bone resorption and bone
formation. Malignant plasma cells secrete osteoclast (OC)
activating factors, such as interleukin-6 (IL-6), receptor activa-
tor of nuclear factor-B ligand (RANKL), and CCL3, which
induce osteoclastogenesis and stimulate OC activity. Moreover,
they also inhibit osteoblast (OB) formation via production of
DKK1, thereby up-regulating OCs. Conversely, OCs support
MM cell survival, inducing tumor cell growth and chemo-
therapy resistance.2 Therefore, new agents targeting this MM-OC
interaction are needed.
Chemokines are chemotactic cytokines involved in regulat-
ing the immune system, mainly by directing the homing of
circulating leukocytes to sites of inflammation.3 They bind G
protein–coupled receptors, thereby stimulating several signaling
pathways.3,4 Chemokines contribute to the pathogenesis of a
variety of diseases3,5; in particular, CCL3 plays a key role in
MM. It stimulates migration and proliferation of MM cells by
activation of Akt and mitogen-activated protein kinase (MAPK)
signaling pathways,6 and promotes OC formation independently
of RANKL.7 Importantly, targeting CCL3 with neutralizing
antibodies or siRNA directly reduces bone lesions and tumor
burden in MM mouse models.8,9 MM cells express both
receptors for CCL3, CCR1, and CCR5.6,10 Moreover, CCR1 is
the major receptor on OC precursor cells and mature OCs11,12;
therefore, CCR1 is a promising novel therapeutic target for
OBD in MM.
In this study, we characterized the effects of a specific CCR1
inhibitor MLN3897 (Millennium Pharmaceuticals, Cambridge,
MA) on formation and function of OCs, as well as on the
interactions between OCs and MM cells. MLN3897 is an oral
clinical-grade small-molecule receptor antagonist currently un-
der evaluation in phase 2 clinical trials for rheumatoid arthritis
and multiple sclerosis. Here, we show that MLN3897 inhibits
osteoclastogenesis and OC activity by impairing multinucle-
ation and by down-regulation of c-fos signaling. It also abro-
gates CCL3-induced MM cell migration by Akt inhibition.
Furthermore, MLN3897 inhibits OC-stimulated MM cell migra-
tion and adhesion, and abrogates the protective effects of OCs
on MM cell survival and proliferation. Taken together, these
data identify a novel mechanism of action for MLN3897 against
osteoclastogenesis and OC-mediated MM survival. These
studies therefore provide the preclinical rationale for the clinical
evaluation of MLN3897 to treat patients with MM-related
OBD.
Submitted May 31, 2007; accepted August 10, 2007. Prepublished online as
Blood First Edition paper, August 21, 2007; DOI 10.1182/blood-2007-
05-093294.
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Patients, materials, and methods
MLN3897
MLN3897, an orally active, small-molecule–specific antagonist of CCR1,
was obtained from Millennium Pharmaceuticals. It has an IC50 of 0.8 nM
for CCR1 and 4 M for CCR5, determined by competition binding assays
of fluorescently labeled CCL3 to CCR1- and CCR5-expressing cells. It is
highly selective for human CCR1 and does not inhibit the effects of CCL3
on mouse leukocytes. Moreover, it does not inhibit RAF, Akt, or receptor
tyrosine kinases at concentrations up to 10 M. MLN3897 was dissolved in
dimethyl sulfoxide (DMSO; Sigma Chemical, St Louis, MO) at 10 mM, and
stored at 20°C until use. For each experiment, it was diluted immediately
before use in culture medium (0.2-100 nM) with less than 0.002% of
DMSO. Since MLN3897 is a highly stable compound with a half-life of
3 days, it was added twice weekly to culture medium.
Cell lines and primary MM cells
Cell lines. The dexamethasone (Dex)–sensitive (MM.1S) human MM cell
line was kindly provided by Dr Steven Rosen (Northwestern University,
Chicago, IL). The INA6 human IL-6–dependent MM cell line was provided
by Dr Renate Burger13 (University of Kiel, Kiel, Germany) and cultured in
the presence of 2.5 ng/mL IL-6 (R&D Systems, Minneapolis, MN). The
OPM1 myeloma cell line was kindly provided by Dr Lief Bergsagel (Mayo
Clinic, Scottsdale, AZ), and the U266 cell line was obtained from the
American Type Culture Collection (Rockville, MD). All MM cell lines
were cultured in RPMI 1640 media (Sigma Chemical) containing 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100
g/mL streptomycin (Gibco, Grand Island, NY).
MM primary cells. Patient tumor cells were isolated as previously
described.14 Briefly, after appropriate informed consent was obtained in
accordance with the Declaration of Helsinki and with approval by the
Institutional Review Board of the Dana-Farber Cancer Institute (Boston,
MA), MM patient cells were separated from bone marrow (BM) samples by
antibody-mediated positive selection using anti-CD138 magnetic activated
cell separation microbeads (Miltenyi Biotech, Gladbach, Germany).
OC formation and activity assays
OC formation and TRAP assay. OCs were generated from peripheral
blood mononuclear cells (PBMCs) from healthy volunteers by Ficoll-Paque
gradient separation and cultured in 6-well or 96-well plates (0.5  106
cells/cm2). After 2 hours, nonadherent PBMCs were removed, and adherent
cells were cultured for 21 days in -MEM containing 10% FBS and 1%
penicillin-streptomycin (Mediatech, Herndon, VA), as well as 50 ng/mL of
macrophage colony-stimulating factor (M-CSF; R&D Systems, Minneapo-
lis, MN) and RANKL (PeproTech, Rocky Hill, NJ). MLN3897 was added
at concentrations and time points as indicated; culture media was replaced
twice weekly. After 3 weeks, cells were fixed with citrate-acetone solution
and stained for tartrate-resistant acid phosphatase (TRAP) using an acid
phosphatase leukocyte staining kit (Sigma Chemical) according to the
manufacturer’s instructions. TRAP OCs containing 3 or more nuclei per
cell were enumerated. Each OC formation assay was performed at least
3 times using PBMCs from different donors.
Pit formation assay. OC activity was assayed by bone resorption
enumerating resorption pits. Briefly, PBMCs were cultured (0.5  106
cells/well) on dentin slices (Immunodiagnostic Systems, Boldon, United
Kingdom) in 96-well plates as per the manufacturer’s guidelines, and then
stimulated with RANKL and M-CSF (50 ng/mL); MLN3897 was added as
indicated. After 3 weeks, adherent cells were scraped off gently with 0.1%
Triton. Bone slices were washed in distilled water and stained with 1%
toluidine solution. Resorption pits were then quantified by light microscopy
using the public domain National Institutes of Health (NIH) Image J
software version 1.36b.15 Each pit area assay was performed at least 3 times
with PBMCs from different donors.
Coculture experiments. OCs were harvested with cell dissociation
buffer (Invitrogen, Carlsbad, CA) and seeded in 96-well or 24-well plates
(approximately 1.5-3  104 cells/cm2). After washing, MM cells were
added to the wells and incubated with media or with MLN3897 (10 nM) for
the specified times at 37°C. For MM cell proliferation, we measured DNA
synthesis by tritiated thymidine uptake (3H-TdR; Perkin Elmer, Boston,
MA), pulsing MM cells with 3H-TdR (0.5 Ci/well [0.0185 MBq]L)
during the last 8 hours of 48-hour cultures. At the end of the culture, cells
were harvested onto paper filters with an automatic cell harvester (Cam-
bridge Technology, Cambridge, MA) and counted using the LKB Betaplate
scintillation counter (Wallac, Gaithersburg, MD). To assess cell survival,
viable MM cells were counted by trypan blue staining.
Cell viability and cell fusion assays of OC precursors
We determined the effects of MLN3897 on viability and fusion of PBMCs
stimulated with RANKL and M-CSF. At different time points, cell number
was quantified using the AlamarBlue assay (BioSource International,
Camarillo, CA), pulsing the cells with AlamarBlue (10 L) and incubating
for 4 hours at 37°C. Absorbance was read at a wavelength of 570 nm (with
correction at 600 nm) on a spectrophotometer (Molecular Devices, Sunny-
vale, CA). To analyze cell fusion, cells were fixed in 3.7% formaldehyde for
5 minutes and then stained with hematoxylin and eosin (Sigma Chemical)
for 5 and 10 minutes, respectively. Cell fusion, evidenced by cells with 3 or
more nuclei, was quantified using light microscopy. Each fusion assay was
performed at least 3 times with PBMCs from different donors.
Analysis of cell-surface marker expression
For analysis of cell-surface marker expression, cells were suspended in
Dulbecco phosphate-buffered saline. Following 30 minutes incubation at
4°C with the primary antibody, cells were washed and analyzed using the
RXP cytomics software on an Epics flow cytometer (Coulter Immunology,
Hialeah, FL). We used affinity-purified monoclonal antibodies specific for
CCR1 (phycoerythrin [PE]–conjugated mouse immunoglobulin IgG2a;
R&D Systems), CCR5 (PE-conjugated mouse immunoglobulin IgG2b;
R&D Systems), CD14 (PE–CyChrome 5–conjugated mouse immunoglobu-
lin IgG2a; Beckman Coulter, Fullerton, CA), and VLA5 (CD49e or
V-integrin, fluorescein isothiocyanate [FITC]–conjugated monoclonal
antibody; Beckman Coulter).
ELISA
CCL3, vascular endothelial growth factor (VEGF), CCL5, and IL-6
expression were analyzed by enzyme-linked immunosorbent assay (ELISA;
R&D Systems). We tested supernatants of MM cell lines, primary MM
cells, monocytes, and mature OCs seeded in RPMI 1640 or -MEM with
10% FBS for 48 hours at a density of 106 cells/mL. IL-6 secretion was also
assessed in 48-hour supernatants of the cocultures between OCs and MM
cell lines. All measurements were done in triplicate.
Transwell migration assay
Cell migration was assayed using a Boyden-modified chamber assay. Cells
were added on an 8-m pore size polycarbonate membrane separating the
2 chambers of a 6.5-mm Transwell (Corning, Corning, NY). CCL3
(5 ng/mL) or 48-hour OC supernatants were added in the lower chamber.
After 5 hours, cells migrating to the lower compartment were counted using
a Coulter Counter ZBII (Beckman Coulter). In specific experiments, cells
were preincubated with MLN3897 (10 nM, 4 hours) and specific PI3K
inhibitor LY294002 (25 M, 1 hour).
Western blotting
Overnight serum-starved cells were stimulated with CCL3 (100 ng/mL for
30 minutes) with or without pretreatment of MLN3897 (10 nM), harvested,
and lysed in lysis buffer (50 mM N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid [pH 7.4], 150 mM NaCl, 1% NP-40, 30 mM sodium
pyrophosphate, 5 mM ethylenediamine tetraacetic acid, 2 mM Na3VO4,
5 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 5 g/mL
leupeptin, and 5 g/mL aprotinin). For OC signaling experiments, adherent
PBMCs were seeded in 6-well plates (0.2  106 cells/cm2), harvested with
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cell dissociation buffer (Invitrogen) after 7 days of stimulation with
RANKL and M-CSF with or without MLN3897, and lysed in lysis buffer.
Samples were then subjected to sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, transferred to PVDF membrane, and immunoblotted with
antibodies against pAkt, Akt, and c-fos (Cell Signaling Technology,
Beverly, MA), phosphorylated extracellular signal–regulated kinase (pERK),
ERK (Santa Cruz Biotechnology, Santa Cruz, CA), or cathepsin K
(Chemicon International, Temecula, CA). Antigen-antibody complexes
were detected by enhanced chemiluminescence (Amersham, Arlington
Heights, IL). The membrane was stripped and reprobed with antitubulin
antibody to ensure equal protein loading. Films were scanned and
densitometric analysis performed using the public domain NIH Image J
program.15
Adhesion assay
To perform adhesion assays, MM cell lines were labeled with calcein AM
(Invitrogen) according to the manufacturer’s instructions and plated in a
96-well plates with OCs, fibronectin (20 g/mL), or media, with or without
MLN3897. After 6 hours of incubation, plates were washed and fluores-
cence of the adherent cells was measured using the Multimode Reader
Mithras LB 940 (Berthold Technologies, Wildbad, Germany).
Statistical analysis
Each experiment was repeated at least 3 times, and all quantitative data are
presented as means plus or minus SD. Statistical comparisons by the
Student 2-tailed t test were considered statistically significant at a P level
less than .05.
Results
MLN3897 inhibits OC formation and activity
Since CCR1 is expressed on the surface of OC precursors and
promotes osteoclastogenesis,11,12 we first investigated whether
MLN3897 inhibited OC formation and function. Adherent PBMCs
from healthy donors were cultured in the presence of RANKL and
M-CSF (50 ng/mL) for 21 days, with or without MLN3897. TRAP
staining was then performed to enumerate multinucleated TRAP
cells. MLN3897 (10 nM) reduced OC number by 40% to 60%
compared with control (Figure 1A; P  .05). No dose-dependent
effect was noted, as doses up to 100 nM did not further decrease
OC number; therefore, all subsequent experiments used a dose of
10 nM MLN3897.
To determine whether inhibition of OC formation by MLN3897
was associated with decreased bone resorption, we performed pit
formation assays. As shown in Figure 1B, almost complete
abrogation of the characteristic resorptive tracks and a reduction of
pit numbers was noted in the presence of MLN3897 (10 nM).
Consistent with the reduction of OC formation, MLN3897 (10 nM)
significantly reduced bone resorption areas (mean 	 SD,
2.4% 	 1.2% vs 8.7% 	 1.9% of total area per slice in the control;
P  .01). Concordantly, cathepsin K expression was decreased
after treatment with MLN3897 (Figure 1C), suggesting that
MLN3897 inhibited differentiation of OC precursors induced by
RANKL and M-CSF.
MLN3897 decreases fusion of OC precursors and
down-regulates c-fos expression
In order to identify the mechanism by which MLN3897 blocks
osteoclastogenesis, we next performed time-course experiments
culturing PBMCs with RANKL and M-CSF in the presence of
MLN3897 (10 nM). The number of TRAP multinucleated cells
was significantly reduced compared with control after exposure
to MLN3897 during the second week of cultures (72 	 18
cells/well compared with 160 	 24 cells/well, respectively;
Figure 2A). Accordingly, adding MLN3897 in the second week
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Figure 1. MLN3897 inhibits OC formation and function. Adherent PBMCs were
cultured for 3 weeks in the presence of RANKL and M-CSF (50 ng/mL) with or without
MLN3897 (0.2-10 nM). (A) Cells were stained for TRAP activity. Multinuclear TRAP cells
are expressed as percentage of control. (B) Adherent PBMCs were cultured on dentine
slices. After 3 weeks, resorption areas were stained with toluidine blue, and pit areas were
quantified by light microscopy using the public domain NIH Image J program. Each value
represents the mean (	 SD) of resorptive areas of at least 3 wells, expressed as a
percentage of total area. Images were obtained using a Leica DM IL microscope equipped
with a 4, 10/0.22, and 20/0.40 numeric aperture objective lens (Leica Microsystems,
Wetzlar, Germany) and acquired through IM50 software (Leica Microsystems Imaging
Solutions, Cambridge, United Kingdom).All experiments were performed independently at
least 3 times. (C) After 3 weeks, we investigated cathepsin K expression on OCs obtained
from 2 different donors and treated with MLN3897 (10 nM). Cells were harvested with cell
dissociation buffer and lysed; proteins were subjected to immunoblotting with anti–
cathepsin K antibody. To ensure equal protein loading, membrane was blotted for tubulin
expression.
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(days 7-14) of PBMC culture resulted in a significant impair-
ment of OC generation (data not shown). These data suggest that
MLN3897 interferes with OC differentiation, after commitment
of precursor cells.
Importantly, CCR1 expression is up-regulated during differen-
tiation of human monocytes to OCs triggered by RANKL and
M-CSF. Compared with unstimulated PBMCs, OC precursors
stimulated by RANKL and M-CSF for 7 days express CCR1 at
high levels (64% vs 12%; Figure 2B), confirming a role for CCR1
at this stage of osteoclastogenesis. Since chemokines mediate the
fusion of OC progenitors into multinucleated TRAP OCs,16 we
next investigated the effects of MLN3897 on the fusion stage by
quantifying multinucleated cells (MNCs) generated in the presence
or absence of MLN3897. Consistent with our time-course TRAP
assays (Figure 2A), MLN3897 inhibits fusion of OC precursors
(Figure 2C); at 7 days, MLN3897 (10 nM) significantly reduced
MNC number by 70% (mean 	 SD, 37 	 11 MNCs/well) com-
pared with control (mean 	 SD, 121 	 16 MNCs/well; P 
 .008).
This inhibitory effect of MLN3897 on OC formation was
not associated with cell death, analyzed by AlamarBlue assay (data
not shown).
Among signaling pathways involved in OC differentiation,
ERK signaling has been shown as a critical regulator of OC
precursor cell fusion.17 Importantly, MLN3897 (10 nM) down-
regulated pERK and its downstream target c-fos,18,19 which are
implicated in cell multinucleation20 (Figure 2D). Our data
therefore suggest that MLN3897 interferes with the fusion of
OC precursors, associated with down-regulation of pERK and
c-fos expression.
MM cells have modest CCR1 expression and secrete CCL3
Although the CCL3/CCR1 pathway mediates several effects in
MM cells, including migration,10 adhesion,21 and proliferation,6
CCR1 expression on MM cell lines is still controversial.6,10,21
We therefore analyzed surface CCR1 expression on several MM
cell lines by flow cytometry (Figure 3A; Table 1). Overall CCR1
expression was modest: MM1.S cells had the highest expression
level (mean fluorescence intensity [MFI] 	 SD, 1.2 	 0.3 vs
0.6 	 0.1 of isotype control [IC]); OPM1 and MM1.R displayed
MFI levels of 1.3 plus or minus 0.5 and 1.5 plus or minus
0.1, respectively, whereas INA6, LR5, RPMI, and U266 did not
Figure 2. MLN3897 blocks fusion of OC precursor cells. (A) Adherent PBMCs cultured with RANKL and M-CSF (50 ng/mL) were exposed to MLN3897 (10 nM) for the
indicated time points. After 3 weeks, TRAP multinucleated cells were stained and counted. Results are expressed as number of TRAP multinucleated cells per well: each
value represents the mean (	 SD) of OCs per well of at least 3 wells. All experiments were performed independently at least 3 times. (B) CCR1 and CD14 coexpression was
analyzed by flow cytometry on human PBMCs cultured with or without RANKL and M-CSF (50 ng/mL) for 7 days. (C) PBMCs were cultured in the presence of RANKL and
M-CSF with or without MLN3897 (10 nM). At the indicated time points, cells were fixed and stained with hematoxylin/eosin. Cells with more than 3 nuclei were enumerated;
images were obtained with a light microscope (Leica Microsystems, Wetzlar, Germany) and acquired through IM50 software (Leica Microsystems Imaging Solutions,
Cambridge, United Kingdom). (D) At day 7, PBMCs stimulated with RANKL and M-CSF (50 ng/mL) in the presence or absence of MLN3897 (10 nM) were harvested and lysed;
proteins were immunoblotted with anti-pERK, ERK, and c-fos antibodies.
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express CCR1 (Figure 3A; Table 1). Consistent with these data,
primary MM cells expressed low levels of CCR1 (MFI,
0.6 	 0.3 compared with 0.5 	 0.2 of IC; Figure 3A; Table 1).
We also analyzed CCR5 expression on 4 cell lines: MM.1S and
OPM1 had the highest CCR1 expression, whereas U266 and
INA6 were both negative for CCR1 expression. MM1.S cells
expressed CCR5 at a lower intensity than CCR1 (MFI, 1 	 0.3
vs IC 0.7 	 0.2), INA6 cells showed modest CCR5 levels (MFI,
1 	 0.5 vs IC 0.7 	 0.2), whereas OPM1 and U266 cell lines
did not express CCR5 (Figure 3B).
Among CCR1 ligands, CCL3 plays a critical role in the
pathogenesis of OBD in MM.7,22 Consistent with previous stud-
ies,6,23 we found that all MM cells secrete CCL3: the mean CCL3
level in culture supernatants of MM cell lines and MM primary
cells was 1180 pg/mL (range, 28-4789 pg/mL) and 255 pg/mL
(range, 35.5-581 pg/mL), respectively. MM1.S and U266 cell
lines secreted high levels of CCL3 (mean 	 SD, 2.8 	 0.24
and 4.8 	 0.17 ng/mL, respectively), while INA6 and OPM1 cell
lines secreted only 45 (	 2.6) and 47 (	 0.9) pg/mL, respectively
(Figure 3C).
MLN3897 inhibits MM cell migration and adhesion
CCL3 is a potent chemoattractant for MM cells,6,10,24 although the
receptor mediating these effects is not defined. We therefore next
investigated whether low doses (5 ng/mL) of CCL3 stimulated MM
cell migration, and whether pretreatment with MLN3897 affected
this response. Interestingly, migration of MM cell lines induced by
CCL3 correlated with the intensity of CCR1 expression. Migration
was induced in MM1.S (1.9-fold) and OPM1 (1.2-fold) cells by
CCL3; conversely, pretreatment with MLN3897 (10 nM for
4 hours) abrogated this response (Figure 4A). No migratory
response to CCL3 was induced in CCR1 cell lines (Figure 4A).
MM1.S cells expressed both receptors for CCL3, CCR1 (14%), and
CCR5 (4%), whereas OPM1 cells expressed only CCR1 (Figure 3;
Table 1), suggesting that CCL3 may bind to both receptors on
MM1.S cells, thereby inducing a stronger migratory response than
in OPM1 cells. Treatment with MLN3897 partially inhibited
MM1.S migration by acting on CCR1, although effects on CCR5
cannot be excluded.
Since Akt is the major downstream molecule in CCL3-
mediated signaling cascade, we examined whether MLN3897
inhibits Akt phosphorylation triggered by CCL3. As expected,
CCL3 (100 ng/mL for 30 minutes) induces Akt phosphoryla-
tion6; conversely, pretreatment with MLN3897 (10 nM for
4 hours) inhibited Akt phosphorylation partially in MM1S and
completely in OPM1 cells (Figure 4B). These results also
suggest that CCL3 may activate both receptors on MM.1S cells,
and that MLN3897 mainly inhibited CCR1-mediated effects. In
contrast, no Akt activation was observed in the CCR1 cell lines
INA6 and U266 (data not shown). Since the PI3K/Akt signaling
pathway is involved in migration induced by several chemo-
kines,25 we next determined whether CCL3 stimulated migration
via PI3K/Akt signaling, using the PI3K inhibitor LY294002.
Pretreatment with either MLN3897 (10 nM for 4 hours) or
LY294002 (25 M for 1 hour) significantly abrogated CCL3-
induced migration in both OPM1 and MM.1S cells (Figure 4C),
suggesting that CCL3 stimulates migration via activating the
PI3K/Akt pathway.
Mature OCs secrete several cytokines.2,26 In 48-hour OC culture
supernatants, we identified CCL3 (mean, 1138.9 pg/mL; range,
68-3768 pg/mL), IL-6 (mean, 159.4 pg/mL; range, 11.3-326.5
pg/mL), VEGF (mean, 115.5 pg/mL; range, 26-343 pg/mL), and
CCL5 (mean, 20.6 pg/mL; range, 12.3-27.5 pg/mL; Figure 5A).
Consistent with these results, 48-hour OC culture supernatants
stimulated MM.1S cell migration by 1.6-fold, whereas no stimula-
tion was noted for INA6 (Figure 5B). Interestingly, pretreatment
with MLN3897 (10 nM) partially inhibited MM1.S cell migration,
Table 1. Expression on MM cell lines and MM patient cells
Cell line IC, MFI ( SD) CCR1, MFI ( SD)
MM1.s 0.6 (	 0.1) 1.17 (	 0.3)
OPM1 0.71 (	 0.2) 1.26 (	 0.5)
MM1.r 1 (	 0.1) 1.46 (	 0.14)
RPMI 1.3 (	 0.5) 1.6 (	 0.3)
LR5 0.48 (	 0.2) 0.56 (	 0.3)
INA6 0.8 (	 0.5) 0.9 (	 0.48)
U266 0.6 (	 0.1) 0.7 (	 0.3)
Primary MM cells 0.5 (	 0.2) 0.6 (	 0.3)
Monocytes 0.7 (	 0.5) 3.47 (	 1)
Figure 3. CCR1 expression and CCL3 secretion by MM cell lines and primary MM cells. (A) CCR1 expression on MM cell lines and patient MM cells was analyzed by flow
cytometry. A representative flow cytometry shows percentage of positive cells from at least 3 different experiments. CCR1 expression on monocytes is shown as a positive
control. (B) CCR5 expression on MM1.S, OPM1, INA6, and U266 was analyzed. Flow cytometry data represent several independent experiments. (C) CCL3 secretion was
assessed by ELISA on 48-hour culture supernatants of MM cell lines, MM primary cells, and monocytes plated at a density of 106 cells/mL. Means (	 SD) are expressed as
pg/mL on a logarithmic scale.
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suggesting that OCs induce migration of MM cells mainly by
CCL3 secretion (Figure 5B).
Chemokine receptors interact with integrins to enhance cell
adhesion by inducing conformational modifications21,27; we
therefore next assessed whether MLN3897 inhibited adhesion
between MM cells and OCs. MM1.S or INA6 cells were plated
onto OCs or fibronectin-coated plates for 6 hours in the presence
or absence of MLN3897. MM cell adhesion to OCs was almost
completely inhibited by MLN3897, independent of CCR1
expression on MM cells (Figure 5C). Importantly, there were no
effects on MM cell adhesion to fibronectin (Figure 5C).
Although previous reports have shown that integrin was up-
regulated by CCL3,8,21 VLA5 surface expression on MM1.S and
INA6 cells was not altered either by CCL3 (5 ng/mL for 6 hours)
or coculture with OC (Figure S1, available on the Blood
website; see the Supplemental Materials link at the top of the
online article). Since mature OCs express surface CCR1
(MFI 	 SD, 2.4 	 1.2; Figure 5D), MLN3897 could impair
adhesion by direct action on OCs. These data suggest that
MLN3897 targets not only MM cells, but also the OC
compartment.
MLN3897 abrogates MM cell survival and proliferative
advantage conferred by OCs
It has been shown that OCs enhance MM cell survival, mainly by
cell-to-cell contact.2 Since MLN3897 almost completely abrogates
adhesion of MM cells to OCs, we next examined the growth
inhibitory effect of MLN3897 in a long-term OC-MM coculture
experiment. OCs were plated in a 24-well plate (3  104 cells/well)
with either INA6 MM cells (5  103 cells/well) or primary patient
MM cells (3  105 cells/well) for 5 days. As shown in Figure 6A,
OCs promote proliferation and survival of MM cells, consistent
with a previous report.2 Importantly, MLN3897 almost completely
abrogated this survival advantage in both INA6 and primary MM
Figure 4. MLN3897 abrogates CCL3-induced migration by inhibiting Akt
phosphorylation. Effects of MLN3897 on cell migration in the presence of CCL3
(5 ng/mL) were assessed by Transwell migration assay. MM cells were preincubated
with MLN3897 (10 nM for 4 hours) (A) or PI3K inhibitor LY94002 (25 M for 1 hour)
(C), and then seeded on the upper chamber of the Transwell plate. After 4 hours, cells
that migrated to the lower chamber were counted, and results were expressed as fold
increase over control plus or minus standard deviation. (B) CCL3 (100 ng/mL for
30 minutes) stimulated Akt phosphorylation in serum-starved (overnight in 1%
and 30 minutes in 0% RPMI media) MM cells, assessed by Western blot analysis.
In selected experiments, cells were preincubated with MLN3897 for 4 hours. The
densitometric analysis of the immunoblots displays partial inhibition of Akt
phosphorylation by MLN3897 in MM.1S and complete inhibition in OPM1 cells.
Results are expressed as mean (	 SD).
Figure 5. MLN3897 inhibits MM cell migration and adhesion to OCs. (A) CCL3,
CCL5, IL-6, and VEGF secretion was assessed by ELISA in OC supernatants at
48 hours; means (	 SD) of 3 independent experiments are expressed as pg/mL on a
logarithmic scale. (B) Effects of MLN3897 on cell migration triggered by 48-hour OC
supernatants, assessed by Transwell migration assay. INA6 and MM1.S cell lines
were preincubated with MLN3897 (10 nM for 4 hours) and seeded in the upper
chamber of the Transwell plate. After 4 hours, cells that migrated to the lower
chamber were counted. Results are expressed as fold increase over control.
(C) Adhesion assay was performed seeding calcein-labeled INA6 and MM1.S cells
on OCs (10 000 cells/well) or fibronectin (FBN; 20 g/mL) in the presence or absence
of MLN3897. After 6 hours, nonadherent cells were washed off, and fluorescence
intensity of adherent cells were expressed as fold increase over control. (D) Repre-
sentative CCR1 expression on mature OCs from 3 different donors, analyzed by flow
cytometry. Results are expressed as MFI (	 SD) of CCR1 and isotype control (IC)
from more than 3 independent experiments.
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cells (Figure 6A). This same effect was also noted in MM1.S cells
(data not shown).
We next analyzed whether MLN3897 affected proliferation of
INA6 MM cells during short-term culture. OCs were seeded in a
96-well plate at a density of 104 cells/well and cocultured with
INA6 cells (3  104 cells/well) for 48 hours. Our data show that
OCs stimulate MM cell proliferation, as assessed at 48 hours by
thymidine uptake, in INA6 cells (3.5-fold increase over that of
control; Figure 6B) and other cell lines (data not shown). Of note,
MLN3897 showed only modest antiproliferative effects on MM
cells alone; however, it blocked induction of proliferation by OCs,
reducing MM cell proliferative response by 50% (P  .05; Figure
6B). Importantly, CCR1 expression on INA6 cells is lacking
(Figure 3A; Table 1), nor is there significant up-regulation of CCR1
expression triggered by coculture with OCs (data not shown).
Coculture of INA6 cells significantly enhanced IL-6 secretion from
OCs (Figure 6C); conversely, MLN3897 reduced IL-6 secretion by
50% (2500 	 182 pg/mL to 1000 	 42 pg/mL), suggesting that
down-regulation of IL-6 secretion accounts, at least in part, for
MLN3897-induced growth inhibition.
Discussion
OCs within the BM compartment are key regulators in the
pathogenesis of MM bone disease. OCs and MM cells interact to
promote the others’ survival and proliferation, thereby contribut-
ing to both OBD and drug resistance. MM cells enhance OC
formation and bone resorption by secretion of osteoclastogenic
cytokines such as RANKL, VEGF, CCL3, and IL-6.9,22,28-30 In
turn, OCs sustain tumor cell survival and protect malignant
plasma cells from chemotherapy-induced apoptosis,2 mainly by
cell-to-cell contact and cytokine secretion. The development of
OBD depends on this loop between OCs and MM cells, and the
involvement of chemokines such as CCL3 is critical. The role of
CCL3 is complex; not only is it secreted by both OCs and MM
cells, but it also interacts with 2 receptors, CCR1 and CCR5,
expressed by both cell types. CCR1 is the most frequent
chemokine receptor on OCs,31 mediating CCL3-induced OC
formation and function.11,21 Furthermore, CCL3 stimulates
migration, adhesion, and survival of MM cells via CCR1 and
CCR5, although the role of each receptor in mediating these
effects remains to be elucidated.6,10,21,24 Here, we studied the in
vitro effects and molecular mechanisms of action of MLN3897,
a novel oral small-molecule CCR1 inhibitor currently undergo-
ing phase 2 clinical testing in multiple sclerosis and rheumatoid
arthritis. MLN3897 impairs OC differentiation by blocking the
fusion process and by down-regulating ERK and c-fos signaling.
Importantly, MLN3897 specifically affects OC-MM cell interac-
tions by abrogation of CCL3 and OC-induced migration of MM
cells, as well as by inhibiting OCs to MM cell adhesion. Finally,
we show that MLN3897 abrogates the survival and proliferative
advantage conferred by OCs to MM cell lines and primary MM
cells. Thus, MLN3897 provides a novel strategy to efficiently
target OBD in MM.
During osteoclastogenesis, precursor cells secrete chemo-
kines such as CCL3, CCL5, and CCL2, thereby enhancing
migration of OC precursor cells and promoting fusion.16,32 The
main receptor for CCL3 on OCs is CCR111,31; conversely, CCR1
inhibition significantly reduces the number of OCs in an in vivo
model.21,24 Consistent with these data, MLN3897 effectively
blocked human PBMC–derived OC formation and OC activity,
mainly by inhibiting fusion of precursor cells. The multinucle-
ation step in OC differentiation is regulated by c-fos.20,33 In
particular, osteoclastogenesis depends on stable c-fos expres-
sion maintained by sustained ERK signaling.34 Here, we show
that treatment with MLN3897 down-regulates pERK and c-fos
Figure 6. MLN3897 overcomes the survival and prolif-
eration advantage conferred by OCs in coculture.
(A) We assessed cell survival of INA6 and MM primary
cells alone and in the presence of OCs, with or without
MLN3897. At 2 and 5 days, viable cells were counted by
trypan blue staining. (B) INA6 cells were cocultured with
mature OCs with or without MLN3897 (10 nM) and cell
proliferation was assessed by thymidine uptake at
48 hours. Results are expressed as means (	 SD)
counts per minute (cpm). (C) At the same time point, IL-6
secretion was evaluated by ELISA. Results are ex-
pressed as mean (	 SD).
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expression, which is associated with inhibition of multinucle-
ated cell formation. Whether these 2 effects are casually related
remains to be determined. Interestingly, MLN3897 does not
completely suppress OC number and activity, suggesting that
other chemokine receptors may partially compensate for the
effects of CCR1 inhibition of OCs.
As previously reported,6,23 almost all MM cell lines and primary
cells secrete CCL3, which is an important mediator of MM effects
on OCs. CCL3 in turn affects MM cells by activation of both CCR1
and CCR5. At present, reports on expression of these receptors on
MM cells are controversial6,7,10,21: Lentzsch et al6 reported surface
CCR5 expression on the MM1.S cell line, whereas Oba et al21
could not identify this receptor at the RNA level. In our series,
surface CCR1 expression on MM cell lines was only modest; 2 cell
lines (MM1.S and OPM1) displayed significant expression levels,
while low levels were observed on primary MM cells. Interestingly,
CCL3-induced migration of MM cells was correlated with CCR1
expression and activation of Akt; conversely, treatment with
MLN3897 inhibited CCL3-induced migration and Akt activation in
MM1.S and OPM1 cells. Since MM1.S cells express both CCL3
receptors, these data indicate that CCR5, in addition to CCR1, may
mediate CCL3 effects, as suggested by prior reports.24 Moreover,
MLN3897 partially inhibited CCL3 effects on MM1.S cell migra-
tion and signaling, suggesting stronger inhibition of CCR1, al-
though effects on CCR5 cannot be excluded.
OCs interact with cancer cells in multiple ways. For example,
OCs secrete cytokines, thereby inducing homing of MM cells to
BM24 in MM and promoting bone metastasis in other solid tumors
like lung cancer.35 Here, we show that OCs promote CCR1 MM
cell migration by secretion of several chemokines, mainly CCL3,
and that pretreatment with MLN3897 efficiently inhibits this effect.
Importantly, we cannot exclude involvement of other chemokines
stimulating MM cell migration and proliferation. Indeed, more than
11 chemokines have been identified as CCR1 ligands4; of these,
CCL3 and CCL7 are secreted by OCs and mediate MM cell
homing to the BM.11,36 Chemokines and their receptors also
enhance cell adhesion by interaction with integrins by modifying
surface expression, lateral mobility, or binding sites.27,37,38 MLN3897
inhibits MM cell–OC cell contact by inhibition of adhesion
regardless of CCR1 expression on tumor cells, suggesting that
CCR1 inhibition mainly targets the OC compartment. Both cyto-
kine secretion and cell-to-cell adhesion are critical mediators of the
survival effects of OCs conferred on MM cells.2 Treatment with
MLN3897 abrogates not only the survival advantage conferred by
OCs to MM cells, but also the enhanced proliferation, due to both
reduced adhesion of MM cells to OCs and impaired cytokine
secretion. In contrast to previous studies,8,21 we did not observe
significant up-regulation of VLA5 surface expression on MM cells
triggered either by stimulation with CCL3 or coculture with OCs,
likely due to the shorter time points we analyzed. Ongoing studies
are addressing the mechanism for the specific inhibitory effect of
MLN3897 on MM cell–to–OC adhesion.
Our data therefore demonstrate that CCR1 inhibition by
MLN3897 may be an effective tool to block and possibly even
prevent OBD in MM. MLN3897 blocks OC development and
function by inhibiting differentiation of OC precursors, in particu-
lar by down-regulating cell fusion and c-fos expression. Moreover,
MLN3897 abrogates MM cell migration and adhesion to OCs, thus
preventing the homing of MM cells to OC sites. Finally, MLN3897
overcomes the protective effect of OCs on MM cell survival and
proliferation, thereby inhibiting the interactive loop between OCs
and MM cells. Ongoing studies are defining the in vivo effects of
MLN3897 in a severe combined immunodeficiency–human (SCID-
hu) mouse model of MM-related osteolysis.39 These data therefore
delineate a novel mechanism of action of MLN3897 on osteoclasto-
genesis and OC–MM cell interactions, and provide the preclinical
rationale for its clinical evaluation to treat OBD in MM.
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